Cited 1 times in
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김종윤 | - |
dc.contributor.author | 박성하 | - |
dc.contributor.author | 이상학 | - |
dc.contributor.author | 이찬주 | - |
dc.date.accessioned | 2022-12-22T04:14:41Z | - |
dc.date.available | 2022-12-22T04:14:41Z | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192078 | - |
dc.description.abstract | Background: There is lacking evidence that telmisartan can improve insulin resistance in patients on high-intensity statins. This study compared the effects of telmisartan and amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease (ASCVD) patients with impaired fasting glucose (IFG) requiring high-intensity rosuvastatin therapy. Methods: Ninety-nine patients were randomly assigned to 2 groups [telmisartan-statin group (n=48) and amlodipine-statin group (n=51)] as add-on therapy to high-intensity rosuvastatin therapy (20 mg). The primary endpoint was to assess insulin resistance using the homeostatic model assessment (HOMA-IR) value at week 24. The secondary endpoint was the change in glucose metabolism indices from baseline to week 24. Results: The HOMA-IR at week 24 (2.4 [interquartile range, 1.8-3.8] versus 2.7 [1.7-3.7]; P = .809) and changes in the HOMA-IR from baseline to week 24 (-7.0 [-29.0 to 21.0] versus -5.5 [-53.3 to 27.3]; P = .539) were not significantly different between 2 groups. However, the fasting glucose level at week 24 was significantly lower in the telmisartan-statin group than in the amlodipine-statin group (107.7 ± 13.4 mg/dL versus 113.3 ± 12.4 mg/dL; P = .039) and significantly decreased in the telmisartan-statin group (-3.2 ± 8.6% versus 3.8 ± 13.2%; P = .003). The proportion of patients with fasting glucose ≥100 mg/dL (71.1% versus 89.6%; P = .047) or new-onset diabetes mellitus (12.5% versus 31.4%, P = .044) at week 24 was also significantly lower in the telmisartan-statin group than in the amlodipine-statin group. Conclusion: In comparison to amlodipine, telmisartan did not decrease the HOMA-IR. However, telmisartan preserved insulin secretion, led to a regression from IFG to euglycemia and prevented new-onset diabetes mellitus in ASCVD patients with IFG requiring high-intensity statins. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.relation.isPartOf | MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Amlodipine / therapeutic use | - |
dc.subject.MESH | Atherosclerosis* / complications | - |
dc.subject.MESH | Cardiovascular Diseases* / complications | - |
dc.subject.MESH | Fasting | - |
dc.subject.MESH | Glucose | - |
dc.subject.MESH | Heart Diseases* / complications | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects | - |
dc.subject.MESH | Hypertension* / chemically induced | - |
dc.subject.MESH | Hypertension* / complications | - |
dc.subject.MESH | Hypertension* / drug therapy | - |
dc.subject.MESH | Insulin Resistance* | - |
dc.subject.MESH | Prediabetic State* / complications | - |
dc.subject.MESH | Rosuvastatin Calcium | - |
dc.subject.MESH | Telmisartan / therapeutic use | - |
dc.title | Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Chan Joo Lee | - |
dc.contributor.googleauthor | Jung-Hoon Sung | - |
dc.contributor.googleauthor | Tae-Soo Kang | - |
dc.contributor.googleauthor | Sungha Park | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.contributor.googleauthor | Jong-Youn Kim | - |
dc.contributor.googleauthor | Byeong-Kuek Kim | - |
dc.identifier.doi | 10.1097/MD.0000000000030496 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00926 | - |
dc.contributor.localId | A01512 | - |
dc.contributor.localId | A02833 | - |
dc.contributor.localId | A03238 | - |
dc.relation.journalcode | J02214 | - |
dc.identifier.eissn | 1536-5964 | - |
dc.identifier.pmid | 36086748 | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김종윤 | - |
dc.contributor.affiliatedAuthor | 박성하 | - |
dc.contributor.affiliatedAuthor | 이상학 | - |
dc.contributor.affiliatedAuthor | 이찬주 | - |
dc.citation.volume | 101 | - |
dc.citation.number | 36 | - |
dc.citation.startPage | e30496 | - |
dc.identifier.bibliographicCitation | MEDICINE, Vol.101(36) : e30496, 2022-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.